• UBS maintains a "Buy" rating for UHS, raising its price target from $280 to $302.
• Remarkable 53% year-over-year increase in earnings per share (EPS), reaching $5.69.
• Revenue growth of 13.4% in the third quarter, with adjusted EBITDA increasing by 27.4%.

Universal Health Services, Inc. (NYSE:UHS) is a prominent player in the healthcare sector, providing acute care and behavioral health services. On October 29, 2025, UBS maintained its "Buy" rating for UHS, reflecting confidence in the company's growth prospects. At the time, UHS's stock was priced at $222.95, with UBS raising its price target from $280 to $302.

UHS's strong financial performance supports UBS's positive outlook. The company reported a remarkable 53% year-over-year increase in earnings per share (EPS) for the third quarter, reaching $5.69. This figure surpassed the Zacks Consensus Estimate by 22%, highlighting UHS's ability to exceed market expectations consistently.

The company's third-quarter revenues rose by 13.4% to $4.5 billion, driven by growth in both the Acute Care and Behavioral Health segments. This revenue figure exceeded the consensus mark by 4.2%. UHS's adjusted EBITDA also saw a substantial increase of 27.4%, reaching $670.6 million, supported by the rise in admissions and patient days.

Despite facing challenges from elevated operating costs, UHS's robust top-line growth and improved segmental revenues underscore its strong market position and operational efficiency. The company's ability to consistently outperform consensus EPS estimates over the past four quarters further solidifies its reputation as a reliable performer in the healthcare industry.

UHS's stock price reflects its strong financial performance, with a current price of $224.54, marking a 2.38% increase. The stock has fluctuated between $217.70 and $224.62 today, with a 52-week high of $226.72 and a low of $152.33. UHS's market capitalization stands at approximately $14.29 billion, with a trading volume of 76,863 shares.